Application Note

Understanding The Microfluidic Platforms For Scaling Nanoparticle Production

Precision NanoSystems Feature
Figure 1. Microfluidic mixing for self-assembly of lipid nanoparticles

COVID-19 vaccines have made RNA lipid nanoparticles (LNPs) known worldwide. The production of RNA-LNP with microfluidic involves mixing RNA in an aqueous buffer with lipids dissolved in ethanol in a non-turbulent, exquisitely controlled manner, resulting in consistent and reproducible LNPs. The process maximizes drug loading, particle quality, and the scope of compositions possible with fully scalable results. Microfluidics can generate LNPs with precisely defined properties but have been limited by challenges in scaling throughput. For the development of RNA therapeutics, the challenge is the development of formulations that require sophisticated and innovative drug delivery nanoparticles consistent across the various scales of drug development.

Learn about the benefits of microfluidics for nanoparticle production over traditional methods as well as scaling nanoparticle production for clinical or industrial use.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Advancing RNA? Subscribe today.

Subscribe to Advancing RNA X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Advancing RNA